Monday, 20 January 2020

Roche starts phase III trial of its eye drug

17 September 2014 | News | By BioSpectrum Bureau

Roche starts phase III trial of its eye drug

The phase II trial of the drug showed a 20 percent reduction in GA lesion progression

The phase II trial of the drug showed a 20 percent reduction in GA lesion progression

Singapore: Swiss drugmaker Roche announced that it has started late-stage trials of its experimental drug, Lampalizumab.

The drug is to be used in the treatment of Geographic Atrophy (GA), a leading cause of blindness in adults over 55.

In this study, the company will investigate how lampalizumab can slow the progression of GA, which affects more than 4.5 million people worldwide.

The phase II trial of the drug showed a 20 percent reduction in GA lesion progression in patients treated monthly with the drug as compared with Sham at 18 months.

"Lampalizumab has the potential to present a significant breakthrough for this disease and could provide real hope. It is the first complement targeted therapy for GA to enter Phase III and the only ophthalmic drug in clinical development that specifically targets complement factor D," said Ms Sandra Horning, Roche's chief medical officer in a statement.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is 2020 demanding timely action of technology adoption in healthcare?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls